Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
Kathryn J. Ruddy(Mayo Clinic in Arizona), Anne Lincoln(Memorial Sloan Kettering Cancer Center), Joseph Vijai(Memorial Sloan Kettering Cancer Center), Christine Rappaport(Memorial Sloan Kettering Cancer Center), Darcy L. Thull(University of Pittsburgh), Paul A. James(The Royal Melbourne Hospital), Fergus J. Couch(Mayo Clinic), Natalie J. Carter(UPMC Health System), Inge Søkilde Pedersen(Aalborg University Hospital), Leigha Senter(Lunenfeld-Tanenbaum Research Institute), Kristin K. Zorn(University of Pittsburgh), Laura Spugnesi(University of Pisa), Anders Bojesen(Vejle Sygehus), Daniel Barrowdale(University of Cambridge), Lenka Foretová(Masaryk Memorial Cancer Institute), Robert L. Nussbaum(National Institutes of Health), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Amanda E. Toland(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Susan J. Ramus(Cancer Institute of New South Wales), Irene L. Andrulis(University of Toronto), Anna Marie Mulligan, Olufunmilayo I. Olopade(University of Chicago), Gord Glendon(University Health Network), Susan L. Neuhausen(City of Hope), Susan M. Domchek(University City Science Center), Valentina Silvestri(Cancer Research UK Cambridge Center), Gero Kramer(Memorial Sloan Kettering Cancer Center), Petra Vašíčková(Masaryk Memorial Cancer Institute), Katherine L. Nathanson(Translational Therapeutics (United States)), Marie Navrátilová(Masaryk Memorial Cancer Institute), Lauren Jacobs(Memorial Sloan Kettering Cancer Center), Peter J. Hulick(NorthShore University HealthSystem), Beth Y. Karlan(University of California, Los Angeles), Uffe Birk Jensen(Aarhus University Hospital), Eva Macháčková(Masaryk Memorial Cancer Institute), Stephen B. Fox(Peter MacCallum Cancer Centre), Mark H. Greene(Cancer Institute (WIA)), Christian F. Singer(Comprehensive Cancer Center Vienna), Emily Hallberg(University of Kansas Medical Center), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Johanna Rantala(Karolinska University Hospital), Timothy R. Rebbeck(University of Pennsylvania), Mads Thomassen(Odense University Hospital), Gillian Mitchell(Peter MacCallum Cancer Centre), Evgeny N. Imyanitov(Institute of Oncology NN Petrov), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Sook-Yee Yoon(University of Pisa)
Cited by 118
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k